Glp-1

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

Hims & Hers Health Stock Is Tumbling Thursday: Here's Why

Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan

Hims & Hers Health Stock Is Tumbling Thursday: Here's Why

Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO

Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'

New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk

Glp-1 Recent News

EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic

Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."

Top 7 Biotech Stock Winners As Weight Loss Drug Battle Escalates: Goldman Sachs Names Best Picks

Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates.

Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic — 'Shame, Blame And The Weight Loss Revolution'

Future Fund co-founder Gary Black shared details about Oprah Winfrey's upcoming TV special discussing her weight loss journey and the use of GLP-1 weight loss drugs, potentially impacting stocks of Novo Nordisk and Eli Lilly, major players in the market.

S&P 500 Sets Sights On 5,400, But Analyst Warns Of Imminent Market Volatility

Bank of America's equity strategist Savita Subramanian has raised the S&P 500 year-end target to 5,400, signaling a 5% upside potential.